Does the media favor CYTK or ONC?

In the previous week, Cytokinetics had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 14 mentions for Cytokinetics and 12 mentions for BeOne Medicines. Cytokinetics' average media sentiment score of 0.15 beat BeOne Medicines' score of 0.02 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RVMD or CYTK?

In the previous week, Revolution Medicines had 3 more articles in the media than Cytokinetics. MarketBeat recorded 17 mentions for Revolution Medicines and 14 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 0.60 beat Cytokinetics' score of 0.15 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CYTK or BNTX more profitable?

BioNTech has a net margin of -44.39% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% BioNTech -44.39% -5.30% -4.62%

Does the media favor CYTK or BNTX?

In the previous week, Cytokinetics had 4 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Cytokinetics and 10 mentions for BioNTech. BioNTech's average media sentiment score of 0.59 beat Cytokinetics' score of 0.15 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CYTK or INSM?

Cytokinetics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytokinetics $88.04M 100.93 -$784.96M -$6.84 N/A Insmed $819.56M 27.44 -$1.28B -$5.75 N/A

Is CYTK or INSM more profitable?

Insmed has a net margin of -144.44% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% Insmed -144.44% -130.11% -51.57%

Does the media prefer CYTK or INSM?

In the previous week, Insmed had 2 more articles in the media than Cytokinetics. MarketBeat recorded 16 mentions for Insmed and 14 mentions for Cytokinetics. Insmed's average media sentiment score of 1.50 beat Cytokinetics' score of 0.15 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CYTK or ROIV?

In the previous week, Cytokinetics had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Cytokinetics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.28 beat Cytokinetics' score of 0.15 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytokinetics (CYTK) Competitors

$71.40 +0.49 (+0.69%)

As of 01:03 PM Eastern

Compare

CYTK vs. ONC, RVMD, BNTX, INSM, and ROIV

Should you buy Cytokinetics stock or one of its competitors? MarketBeat compares Cytokinetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytokinetics include BeOne Medicines (ONC), Revolution Medicines (RVMD), BioNTech (BNTX), Insmed (INSM), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Cytokinetics compare to BeOne Medicines?

Cytokinetics (NASDAQ:CYTK) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

48.6% of BeOne Medicines shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BeOne Medicines has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	100.93	-$784.96M	-$6.84	N/A
BeOne Medicines	$5.34B	5.69	$286.93M	$4.47	61.96

In the previous week, Cytokinetics had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 14 mentions for Cytokinetics and 12 mentions for BeOne Medicines. Cytokinetics' average media sentiment score of 0.15 beat BeOne Medicines' score of 0.02 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a net margin of 8.94% compared to Cytokinetics' net margin of -784.02%. BeOne Medicines' return on equity of 12.06% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
BeOne Medicines	8.94%	12.06%	6.69%

Cytokinetics presently has a consensus price target of $99.30, suggesting a potential upside of 39.06%. BeOne Medicines has a consensus price target of $390.00, suggesting a potential upside of 40.82%. Given BeOne Medicines' higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

94.3% of Revolution Medicines shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Revolution Medicines had 3 more articles in the media than Cytokinetics. MarketBeat recorded 17 mentions for Revolution Medicines and 14 mentions for Cytokinetics. Revolution Medicines' average media sentiment score of 0.60 beat Cytokinetics' score of 0.15 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revolution Medicines has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Cytokinetics	-784.02%	N/A	-52.86%

Cytokinetics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,838.89	-$1.13B	-$7.07	N/A
Cytokinetics	$88.04M	100.93	-$784.96M	-$6.84	N/A

Revolution Medicines currently has a consensus price target of $123.72, suggesting a potential downside of 19.99%. Cytokinetics has a consensus price target of $99.30, suggesting a potential upside of 39.06%. Given Cytokinetics' higher possible upside, analysts plainly believe Cytokinetics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Summary

Revolution Medicines beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to BioNTech?

Cytokinetics (NASDAQ:CYTK) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Cytokinetics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	100.93	-$784.96M	-$6.84	N/A
BioNTech	$3.25B	6.88	-$1.29B	-$5.88	N/A

BioNTech has a net margin of -44.39% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
BioNTech	-44.39%	-5.30%	-4.62%

15.5% of BioNTech shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cytokinetics had 4 more articles in the media than BioNTech. MarketBeat recorded 14 mentions for Cytokinetics and 10 mentions for BioNTech. BioNTech's average media sentiment score of 0.59 beat Cytokinetics' score of 0.15 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Cytokinetics presently has a consensus price target of $99.30, indicating a potential upside of 39.06%. BioNTech has a consensus price target of $129.56, indicating a potential upside of 46.71%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Summary

BioNTech beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Insmed?

Cytokinetics (NASDAQ:CYTK) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Cytokinetics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	100.93	-$784.96M	-$6.84	N/A
Insmed	$819.56M	27.44	-$1.28B	-$5.75	N/A

Insmed has a net margin of -144.44% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Insmed	-144.44%	-130.11%	-51.57%

Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Cytokinetics presently has a consensus price target of $99.30, suggesting a potential upside of 39.06%. Insmed has a consensus price target of $210.95, suggesting a potential upside of 103.31%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Insmed had 2 more articles in the media than Cytokinetics. MarketBeat recorded 16 mentions for Insmed and 14 mentions for Cytokinetics. Insmed's average media sentiment score of 1.50 beat Cytokinetics' score of 0.15 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Insmed beats Cytokinetics on 10 of the 15 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Cytokinetics (NASDAQ:CYTK) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Cytokinetics has a net margin of -784.02% compared to Roivant Sciences' net margin of -3,629.19%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cytokinetics currently has a consensus price target of $99.30, indicating a potential upside of 39.06%. Roivant Sciences has a consensus price target of $33.59, indicating a potential upside of 17.66%. Given Cytokinetics' stronger consensus rating and higher possible upside, research analysts plainly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Cytokinetics had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Cytokinetics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.28 beat Cytokinetics' score of 0.15 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has lower revenue, but higher earnings than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	100.93	-$784.96M	-$6.84	N/A
Roivant Sciences	$8.26M	2,486.10	-$299.77M	-$0.60	N/A

Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Summary

Cytokinetics beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.89B	$3.26B	$6.26B	$12.44B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-10.44	17.75	22.35	24.23
Price / Sales	100.93	323.71	555.60	126.08
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	-13.25	6.55	9.82	6.73
Net Income	-$784.96M	$24.20M	$3.56B	$336.97M
7 Day Performance	-7.44%	-3.25%	-1.16%	0.79%
1 Month Performance	12.72%	0.48%	3.85%	5.38%
1 Year Performance	123.16%	47.06%	27.33%	34.55%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	2.7838 of 5 stars	$71.40 +0.7%	$99.30 +39.1%	+127.2%	$8.88B	$88.04M	N/A	250	Insider Trade
ONC BeOne Medicines	4.4002 of 5 stars	$310.25 flat	$389.15 +25.4%	+11.7%	$34.04B	$5.34B	69.41	12,000	Analyst Forecast
RVMD Revolution Medicines	2.2813 of 5 stars	$151.56 flat	$111.35 -26.5%	+272.2%	$32.22B	$11.58M	N/A	250	Analyst Forecast Analyst Revision
BNTX BioNTech	3.6845 of 5 stars	$92.14 flat	$128.44 +39.4%	-21.2%	$23.30B	$3.25B	N/A	7,807	Analyst Forecast
INSM Insmed	3.7769 of 5 stars	$106.24 flat	$210.95 +98.6%	+44.7%	$23.03B	$606.42M	N/A	1,664	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors

CYTK vs. ONC, RVMD, BNTX, INSM, and ROIV

How does Cytokinetics compare to BeOne Medicines?

Summary

How does Cytokinetics compare to Revolution Medicines?

Summary

How does Cytokinetics compare to BioNTech?

Summary

How does Cytokinetics compare to Insmed?

Summary

How does Cytokinetics compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Competitors

CYTK vs. ONC, RVMD, BNTX, INSM, and ROIV

How does Cytokinetics compare to BeOne Medicines?

Do insiders and institutionals hold more shares of CYTK or ONC?

Which has stronger valuation & earnings, CYTK or ONC?

Does the media favor CYTK or ONC?

Is CYTK or ONC more profitable?

Do analysts recommend CYTK or ONC?

Which has more risk and volatility, CYTK or ONC?

Summary

How does Cytokinetics compare to Revolution Medicines?

Do institutionals and insiders have more ownership in RVMD or CYTK?

Does the media prefer RVMD or CYTK?

Is RVMD or CYTK more profitable?

Which has preferable earnings and valuation, RVMD or CYTK?

Do analysts rate RVMD or CYTK?

Which has more volatility and risk, RVMD or CYTK?

Summary

How does Cytokinetics compare to BioNTech?

Which has better earnings and valuation, CYTK or BNTX?

Is CYTK or BNTX more profitable?

Do insiders and institutionals believe in CYTK or BNTX?

Does the media favor CYTK or BNTX?

Which has more risk and volatility, CYTK or BNTX?

Do analysts recommend CYTK or BNTX?

Summary

How does Cytokinetics compare to Insmed?

Which has preferable valuation and earnings, CYTK or INSM?

Is CYTK or INSM more profitable?

Which has more volatility & risk, CYTK or INSM?

Do analysts prefer CYTK or INSM?

Does the media prefer CYTK or INSM?

Summary

How does Cytokinetics compare to Roivant Sciences?

Is CYTK or ROIV more profitable?

Do insiders & institutionals hold more shares of CYTK or ROIV?

Do analysts rate CYTK or ROIV?

Does the media prefer CYTK or ROIV?

Which has better earnings and valuation, CYTK or ROIV?

Which has more volatility & risk, CYTK or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools